We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 17,874

The motivation to combine references: substantial evidence and the obviousness examination guidelines

  • Wyatt Tarrant & Combs LLP
  • -
  • USA
  • -
  • March 30 2015

A recent opinion by a Federal Circuit panel demonstrates that three years can be a long time in the smartphone industry. MobileMedia Ideas, LLC v

PTAB’s “quick-fixes” for AIA rules are to be implemented immediately

  • Fish & Richardson PC
  • -
  • USA
  • -
  • March 28 2015

In a blog post on the USPTO's website, Under Secretary of Commerce for Intellectual Property and Director of the USPTO Michelle K. Lee, announced

Did Teva alter the standard for invalidating a patent for indefiniteness?

  • Dickinson Wright PLLC
  • -
  • USA
  • -
  • March 27 2015

As discussed in the concurrent article, prior to the Supreme Court's decision in Teva Pharmaceuticals v. Sandoz, Inc.,574 U.S. ___ , No. 13-854, slip

Slowing patent trolls: RPX’s open

  • Holland & Knight LLP
  • -
  • USA
  • -
  • March 27 2015

RPX has begun a new, free program OPEN that seeks to increase transparency in the patent marketplace, while also reducing transaction costs and

Inter partes review (IPR): an alternative pathway for biosimilars

  • Baker Botts LLP
  • -
  • USA
  • -
  • March 27 2015

A "biosimilar" is a biological product, e.g., a therapeutic antibody, that is not only highly similar to an existing FDA-approved biological product

Teva Pharmaceuticals: is it time to rethink how you will argue claim construction?

  • Dickinson Wright PLLC
  • -
  • USA
  • -
  • March 27 2015

The United States Supreme Court decided in Teva Pharmaceuticals USA Inc. v. Sandoz Inc. that the Federal Circuit must review all subsidiary factual

First in three-part roll-out of AIA rule changes announced, including page limits for Petitioner Replies and Patent Owner Motions to Amend

  • Ropes & Gray LLP
  • -
  • USA
  • -
  • March 27 2015

March 27, 2015 - In a blog post today, U.S. Patent and Trademark Office ("PTO") Director Michelle K. Lee announced plans for a three-part roll-out of

Order of steps serves to differentiate prior art

  • Sughrue Mion PLLC
  • -
  • USA
  • -
  • March 27 2015

In Facebook v. Software Rights Archive, three online service companies challenged two Software Rights’ patents 5,832,494 (“the '494 patent) and 6,233

PTAB moves forward on quick-fix rule changes

  • OBLON
  • -
  • USA
  • -
  • March 27 2015

The USPTO's Patent Trial & Appeal Board (PTAB) has announced some of their "quick fix" rule changes today in advance of the anticipated Federal

Strike two FDA rejects Amgen’s certification petition for biosimilar applicants

  • Sterne Kessler Goldstein & Fox
  • -
  • USA
  • -
  • March 27 2015

In parallel with the district court case where Amgen is asserting that Sandoz has not complied with the BPCIA because they have not provided Amgen